MDT

86.1

+0.48%↑

114.78

+1.59%↑

VEEV

174.13

-0.49%↓

HQY

83.51

+1.56%↑

PHR.US

8.56

+6.47%↑

MDT

86.1

+0.48%↑

114.78

+1.59%↑

VEEV

174.13

-0.49%↓

HQY

83.51

+1.56%↑

PHR.US

8.56

+6.47%↑

MDT

86.1

+0.48%↑

114.78

+1.59%↑

VEEV

174.13

-0.49%↓

HQY

83.51

+1.56%↑

PHR.US

8.56

+6.47%↑

MDT

86.1

+0.48%↑

114.78

+1.59%↑

VEEV

174.13

-0.49%↓

HQY

83.51

+1.56%↑

PHR.US

8.56

+6.47%↑

MDT

86.1

+0.48%↑

114.78

+1.59%↑

VEEV

174.13

-0.49%↓

HQY

83.51

+1.56%↑

PHR.US

8.56

+6.47%↑

Home・Akcijų sąrašas・VolitionRX Ltd

VolitionRX Ltd

Atidarymo kaina

0.18 -5.26

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

0.18

Max

0.2

Pagrindiniai rodikliai
By Trading Economics
Pajamos	936K -5.4M
Pardavimai	221K 627K
Pelno marža	-857.414
Darbuotojai	75
EBITDA	1.3M -4.2M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+1400% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-14

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-19M 28M
Ankstesnė atidarymo kaina	5.44
Ankstesnė uždarymo kaina	0.18

VolitionRX Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-31 23:31; UTC

Karštos akcijos

Stocks to Watch: Nike, RH, NCino

2026-03-31 22:35; UTC

Uždarbis

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

2026-04-01 00:00; UTC

Įsigijimai, susijungimai, perėmimai

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

2026-03-31 23:50; UTC

Įsigijimai, susijungimai, perėmimai

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

2026-03-31 23:43; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

2026-03-31 23:33; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

2026-03-31 23:21; UTC

Uždarbis

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

2026-03-31 23:14; UTC

Rinkos pokalbiai

Uždarbis

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

2026-03-31 23:12; UTC

Rinkos pokalbiai

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

2026-03-31 22:36; UTC

Uždarbis

China Vanke 2025 Loss Widens >000002.SZ

2026-03-31 22:36; UTC

Uždarbis

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

2026-03-31 22:36; UTC

Uždarbis

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

2026-03-31 22:36; UTC

Uždarbis

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

2026-03-31 22:36; UTC

Uždarbis

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

2026-03-31 21:46; UTC

Įsigijimai, susijungimai, perėmimai

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

2026-03-31 21:36; UTC

Rinkos pokalbiai

West African Resources's Costs Higher Than Bull Expected -- Market Talk

2026-03-31 21:35; UTC

Uždarbis

Nike Expects China Sales Down 20% in 4Q, CFO Says

2026-03-31 21:35; UTC

Uždarbis

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

2026-03-31 21:35; UTC

Uždarbis

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

2026-03-31 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

2026-03-31 21:33; UTC

Uždarbis

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

2026-03-31 21:32; UTC

Uždarbis

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

2026-03-31 21:28; UTC

Uždarbis

Nike Expects to End 4Q With Elevated Inventory, CFO Says

2026-03-31 21:26; UTC

Uždarbis

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

2026-03-31 21:25; UTC

Uždarbis

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

2026-03-31 21:24; UTC

Rinkos pokalbiai

Uždarbis

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

2026-03-31 21:22; UTC

Uždarbis

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

2026-03-31 21:22; UTC

Uždarbis

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

2026-03-31 21:21; UTC

Uždarbis

Nike's Digital Channel Still Too Promotional, CFO Says

2026-03-31 21:20; UTC

Uždarbis

Nike CEO: Converse Remains Important to Portfolio

Akcijų palyginimas

Kainos pokytis

VolitionRX Ltd Prognozė

Kainos tikslas

By TipRanks

1400% į viršų

12 mėnesių prognozė

Vidutinis 3 USD 1400%

Aukščiausias 3 USD

Žemiausias 3 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines VolitionRX Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

Pirkti

Laikyti

Parduoti

Remiantis 1 analitikų, pateikusių VolitionRX Ltd akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę VolitionRX Ltd

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.